Shots:
- Polpharma Biologics has entered into a licensing agreement with Tuteur to commercialize a biosimilar candidate for autoimmune diseases across Latin America, excl. Brazil
- As per the deal, Tuteur will handle commercialization, marketing, & distribution in the licensed territories, while Polpharma will be responsible for the development & manufacturing of the biosimilar candidate
- The biosimilar candidate is being developed as a potentially effective and well-tolerated treatment for autoimmune conditions, with regulatory submission expected within the next 3yrs.
Ref: Businesswire | Image: Polpharma & Tuteur | Press Release
Related News: Polpharma Biologics and Libbs Farmacêutica Enter into a Licensing Agreement for an Autoimmune Biosimilar
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
